Inositol Hexanicotinate (Flush-Free Niacin)
Sold as niacin without the flush. It avoids the flush because it barely releases free nicotinic acid, and the controlled trial that tested it found no effect on cholesterol at all.
Evidence last reviewed: August 2026
What the science says
- Lipid lowering Limited evidence
A 6-week blinded, placebo-controlled trial randomised 120 adults with mild-to-moderate dyslipidaemia to 1500 mg/day of wax-matrix extended-release niacin, 1500 mg/day of inositol hexanicotinate, or placebo. The niacin arm improved LDL by 18% and HDL by 12%, while inositol hexanicotinate was indistinguishable from placebo.
- Absence of flushing Moderate evidence
It does reliably avoid the niacin flush, but the pharmacokinetic substudy in the same trial indicates this is because very little free nicotinic acid is released, which is also why the lipid effect is absent. The absence of the flush is a marker of the absence of the drug effect.
- Correcting niacin deficiency Limited evidence
As a vitamin B3 source it can plausibly meet basic niacin requirements, but the lipid-modifying dose and the vitamin dose are entirely different things, and this product delivers neither reliably.
Dosage & safety
Scientific references
Where to buy
Referral link — this site may earn a commission on purchases.
Related in Heart & metabolic
- Vitamin B3 (Niacin) Limited evidence
- Vitamin K2 (MK-7) Limited evidence
- Chromium Limited evidence
- Potassium Strong evidence
- Vanadium Limited evidence
- L-Arginine Moderate evidence